GlassScriptPhysician profile
Diana Li
NPI 1396242871
$4,197.82
in general payments reported to CMS, 2019-2025
35 companies · $2,029 in 2025
The $2,029 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $22.19 · 2023: $899 · 2024: $1,248 · 2025: $2,029.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,175.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,318.76 | 2023-2025 | |
| Pfizer INC. | $343.39 | 2025 | |
| Lilly USA, LLC | $262.82 | 2022-2024 | Emgality, Kisunla, Reyvow |
| Axsome Therapeutics, INC. | $229.93 | 2025 | Symbravo |
| Argenx US, INC. | $194.48 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Sk Life Science, INC. | $167.36 | 2023-2024 | Xcopri |
| Tg Therapeutics, INC. | $161.39 | 2023-2024 | |
| Scilex Pharmaceuticals INC. | $156.22 | 2024 | |
| Lundbeck LLC | $143.29 | 2023-2025 | Vyepti |
| Teva Pharmaceuticals USA, INC. | $125.84 | 2023-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Genentech USA, INC. | $110.20 | 2023-2025 | Ocrevus Zunovo, Ocrevus |
| Ipsen Biopharmaceuticals, INC | $86.57 | 2023-2024 | Dysport |
| Alexion Pharmaceuticals, INC. | $83.86 | 2023-2024 | Ultomiris |
| Livanova USA, INC. | $76.61 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Astrazeneca Pharmaceuticals LP | $68.97 | 2024-2025 | Wainua |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $68.10 | 2024-2025 | Hizentra |
| Takeda Pharmaceuticals U.S.A., INC. | $67.56 | 2024-2025 | Hyqvia |
| Otsuka America Pharmaceutical, INC. | $57.41 | 2024-2025 | Rexulti |
| Impel Pharmaceuticals INC. | $42.46 | 2023 | Trudhesa |
| Merz Pharmaceuticals, LLC | $42.30 | 2024-2025 | Inbrija, Ampyra |
| Neurelis, INC. | $41.04 | 2024-2025 | Valtoco |
| Grifols USA, LLC | $40.96 | 2025 | Gamunex-C |
| Impel Pharmaceuticals LLC | $39.14 | 2025 | Trudhesa |
| Mallinckrodt Hospital Products INC. | $32.19 | 2025 | Acthar |
| Jazz Pharmaceuticals INC. | $31.89 | 2023 | |
| Sumitomo Pharma America, INC. | $31.38 | 2023 | Aptiom |
| Aucta Pharmaceuticals, INC. | $29.87 | 2025 | Motpoly Xr |
| Vanda Pharmaceuticals INC. | $28.34 | 2025 | Ponvory |
| Janssen Biotech, INC. | $24.51 | 2025 | |
| Emd Serono, INC. | $19.99 | 2025 | |
| Eisai INC. | $15.07 | 2024 | |
| Alnylam Pharmaceuticals INC. | $14.73 | 2025 | Onpattro |
| Tanabe Pharma America, INC. | $14.69 | 2025 | Radicava |
| Azurity Pharmaceuticals, INC. | $13.85 | 2024 | Horizant |
| Corium, LLC | $12.65 | 2023 | Adlarity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diana Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.